Articles On Rhythm Biosciences (ASX:RHY)

ASX stages swift recovery, climbing 0.89% or 78 points 10 of 11 sectors on the up; just utilities left in the cold Info tech and materials lead gains   Market powers through RBA rate hike The market recovered its footing after four sessio...

Highlights Market sentiment steadied as global cues improved Resources and technology shares regained momentum Central bank focus shaped cautious positioning Australian shares regained balance as technology and resourc...

Host Tylah Tully looks at Rhythm Biosciences (ASX:RHY) latest news after the company secured a key manufacturing partner in the US, moving closer to the commercial rollout of its colorectal cancer blood test, ColoSTAT. Rhythm has executed a...

ASX recovers from session lows of -0.84% to dip just -0.07% Info Tech extends losses, falling to Feb 2024 levels Uranium and gold stocks fuel materials and energy gains   Tech in harsh retreat The struggling info tech sector took another...

Rhythm partners with Australian Genome Research Facility to establish Australian commercial-scale processing for geneType The partnership will process more than 100,000 tests per year to support local customer demand Partnership to support...

Rhythm Biosciences secures US platform partnership with CancerIQ to accelerate geneType commercial adoption Cancer IQ is a leading US digital oncology platform used by more than 65 health systems encompassing 345 clinics Partnership positi...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

ASX slides again, down 0.37% Eight of 11 sectors lower, with 112/200 stocks falling Materials surges on gold price once again   Materials pumps higher on fresh gold peak The materials sector has truly become the engine room of the ASX in...

First peer-reviewed publication validates the first generation ColoSTAT clinical performance with 81.3% sensitivity and 91.% specificity The performance is comparable to stool-based test used in Australia’s National Bowel Cancer Screening...

ASX gives up early gains, ticking up just 12 points or 0.14% Weak breadth despite eight sectors green with just 101 stocks rising Banks and financial stocks weigh heavy   Market gives up momentum on bank slide A spike in oil prices pushin...

Enhanced geneType colorectal cancer test now includes genetic, clinical and lifestyle risk factors New gender-specific variables deliver stronger predictive accuracy Peer-reviewed validation confirms improved performance of new model   Sp...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin MELBOURNE, Australia, Jan. 14, 2026 /PRNewswire/ – Rhythm Biosciences Ltd (‘RHY‘,...

ASX climbs 0.15% on solid breadth with 143 stocks rising 8 of 11 sectors higher, led by info tech Banks retreat despite cooling inflation read Rare Earth export restrictions spotlights ASX stocks The ASX 200 finished up 0.15% or 12.8 poin...

Just 3 of 11 sectors made gains in December Gold and silver hit new all-time highs Analysts are predicting an interest rate hike by February Santa Rally fails to fully materialise The ASX 200 had a lacklustre performance in December, addi...

ASX bounces 95.8 points, adding 1.1pc Broad gains once again with all sectors higher Real estate, banks, lead market higher   Broad strength, strong breadth The ASX 200 is already sipping the eggnog if today’s performance is anything to g...

Rhythm and US-based datma team up to apply federated real-world data to genomic diagnostic development Rhythm to evaluate how datma.FED platform may contribute to further development of its genomic-integrated cancer risk prediction tools...

ASX 200 falls 0.16% or 13.7 points 10 of 11 sectors down with 98 stocks lower and 93 rising Materials alone in the green as XGD touches new record high   Gold and lithium stocks resist the tide A familiar game of tug-of-war played out on...

Host Tylah Tully sits down with Rhythm Biosciences (ASX:RHY) CEO and managing director David Atkins after the company reached a long-awaited commercial milestone, officially bringing its flagship ColoSTAT bowel cancer screening test to mark...

ASX climbs 105.3 points, or 1.23%, on broad rally Eight of 11 sectors on the up with 138 stocks rising XGD hits new all-time high after surging 4.42%   XGD gold index rises to new heights The ASX 200 had its best showing in a month, risin...

Rhythm starts commercialisation in Australia of its flagship blood test for bowel cancer ColoSTAT The launch follows renewal of its ISO accreditation, marking its transition to its first market launch ColoSTAT will initially be offered as...

Highlights Gold and silver extend strong overnight gains ASX 200 lifts as resources lead early trading Broader sector support follows renewed market confidence Precious metals strength supported broad market improvemen...

Highlights Gold strength boosts market sentiment Resource activity spreads into wider sectors Small caps respond with renewed traction Renewed gold strength lifted the Australian market, prompting activity across resou...

Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am in the east, once trading kicks...

ASX trades sideways ahead of US Fed decision overnight Eight of 11 sectors down, weak breadth with 121/200 stocks falling Materials sector propped up by gold and silver prices   ASX trades sideways The ASX 200 is still in wait-and-see mod...

Host Tylah Tully looks at news from Rhythm Biosciences (ASX:RHY), as it looks to push its ColoSTAT blood test for bowel cancer as a new potential screening tool in England. Rhythm has partnered with the Southern Hub Research Team at the Roy...

Cogstate shares plunge on revenue and earnings downgrade Immuron shares have the runs after failed US military trial Was Immutep’s share price reaction underdone?   CogState (ASX:CGS) shares have tumbled as much as 30% on the back of a r...

Rhythm Biosciences has entered a US marketing partnership with cancer prevention platform Catch Bio Under the deal Rhythm’s geneType cancer risk assessment test will be introduced to Catch Bio’s growing US member base The geneType test wil...

The ASX 200 jumped 0.15% to a session high after the RBA held rates before plunging to -0.45% Bloodbath across sectors and indices, lower across the board Strong gains in some lithium and defence stocks despite bearish market ASX ducks a...

Immutep has struck a global deal to commercialise its novel immuno-oncology asset Broker Morgans values Epiminder shares at $2.33 – almost twice their current value Rhythm gets into the US groove with genetic test deal   Shares in immuno-...

Host Tylah Tully sits down with Rhythm Biosciences (ASX:RHY) managing director and CEO David Atkins to discuss the company’s updated ISO accreditation for its GeneType business. While the update ensures the continued sale of GeneType’s clin...

ASX healthcare sector gains 1.99% in November while benchmark ASX 200 down 2.66% Mach7 rises 50% in November with health imaging stock outlining a growth strategy at its AGM  Island Pharmaceuticals rises after FDA confirms Galidesivir will...

ASX adds just 14.5 points in subdued day of trade Broad rally in commodity prices lifts resource stocks Crude oil bounces 1.3% as Ukraine continues to strike Russian oil infrastructure   ASX grinds higher on commodity strength A fresh att...

Rhythm transitions geneType Laboratory to ISO 15189:2022 and secures updated accreditation ISO 15189:2022 is the latest international standard for medical laboratories Milestone demonstrates company’s commitment to world-class laboratory s...

RHY’s geneType twice as effective at identifying women with elevated ovarian cancer risk than using clinical or genetic information alone Peer-reviewed study validates Rhythm’s ovarian cancer risk prediction model Cross-validation across t...

ASX healthcare sector fell 4.83% in October and is down more than 19% YTD CSL shares fall more than 15% on October 28 after management trims FY26 guidance Nyrada surges 165% in October on board changes and progress in phase 2a trial    Wi...

Rhythm’s ColoSTAT demonstrates conclusive performance in patients aged 45 to 80 diagnosed with colorectal cancer ColoSTAT performance consistent across both males and females Data indicates potentially suitable for early onset cancer in pa...

October marks Global Breast Cancer Awareness Month with several ASX companies working to advance early detection and treatments for better outcomes Imagion’s first-of-its-kind imaging agent tech MagSense uses targeted nanoparticles to enha...

Tylah Tully chats with Rhythm Biosciences (ASX:RHY) Director of Clinical and Scientific Affairs Dr Erika Spaeth, who explains the growing role of polygenic risk scores (PRS) in preventive healthcare. Dr. Spaeth highlights Rhythm’s GeneType...

The S&P ASX 200 Health Care index fell 13.21% in August as a tough reporting season weighed on sector CSL had its biggest ever one day fall on August 19, down 17% following softer FY25 results and restructure plans Despite the broader...

Tylah Tully chats with Dr Andy Feber, who works in Clinical R&D Translational Oncology and as an external advisor to Rhythm Biosciences (ASX:RHY). Rhythm has just completed the final full system validation of its ColoSTAT, a diagnostic...

Rhythm enters co-marketing deal with geneType to be available on Know Your Lemons mobile app Partnership aligns with Breast Cancer Awareness Month in October, supporting proactive healthcare for women Reaching hundreds of thousands of wome...

ASX slides 0.41pc as full year results disappoint Gold, Small Ords, Tech index enjoy late interest-rate-related rally Consumer staples and Coles soften blow   Coles results plus late gold rally soothes market The ASX spent the vast majori...

Rhythm completes final full system validation of ColoSTAT for the kits, algorithm and instrumentation using range of clinical samples Validation shows simple blood test to detect colon cancer will meet needs for intended clinical indicatio...

Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am in the east, once trading kicks...

Artrya shares surge up to 42% on FDA clearance of the company’s Salix Coronary Plaque device Sonic Healthcare joins CSL in the healthcare sin bin Universal Biosensors calls in the corporate undertakers   Artrya (ASX:AYA) has won US Food a...

Tylah Tully chats with Rhythm Biosciences (ASX:RHY) CEO and managing director David Atkins about the company’s recently completed $3.75 million placement. Atkins explains that strong demand from both existing and new shareholders allowed Rh...

Rhythm Biosciences to undertake capital raise of up to $3.75 million Proceeds to advance its products including blood test to detect colorectal cancer ColoSTAT progresses toward commercial release following validation of second-generation...

 Pro Medicus shares surge up to 7% on record revenue and earnings Tetratherix pockets $3.3 million, while Rhythm girds for a raising CEO oration inspires Starpharma share run   The $32 billion market cap ProMedicus (ASX:PME) has drawn the...

Bulls N’ Bears ASX Runner of the Week is… Rhythm Biosciences, after the company revealed promising results from a study of its simple bowel cancer diagnostic blood test.